Table 2.
Median sum of 5-HT syndrome and AIMs scores (± MAD) after injection of 5-HT compounds and L-DOPA
| 5-HT syndrome | LID | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total 5-HT syndrome score | Lower lip retraction | Flat body posture | Forepaw treading | Straub tail | Resting tremor | Hindlimb abduction | Lateral head-weaving | Total AIMs score | |
| Vehicle | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 64 ± 7.5 |
| ±8-OH-DPAT 0.3 mg·kg−1 | 35* ± 2.5 | 15* ± 1 | 11* ± 1 | 5.5* ± 2 | 2* ± 1 | 1 ± 1 | 0 ± 0 | 0 ± 0 | 24* ± 5 |
| ±8-OH-DPAT 1 mg·kg−1 | 57.5* ± 3.5 | 18* ± 0 | 16* ± 1 | 11* ± 2 | 3* ± 2 | 7* ± 1.5 | 0.5 ± 0.5 | 0 ± 0 | 5* ± 2 |
| Buspirone 1 mg·kg−1 | 12.5* ± 3.5 | 7* ± 2 | 6* ± 2 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 29.5* ± 7.5 |
| Buspirone 3 mg·kg−1 | 23* ± 2.5 | 13* ± 2 | 9* ± 1 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 12* ± 6 |
| Citalopram 2 mg·kg−1 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 30* ± 9 |
| Citalopram 5 mg·kg−1 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 0 ± 0 | 11.5* ± 6.5 |
Rats (n = 20) were injected with ±8-OH-DPAT, buspirone or citalopram and rated for 5-HT syndrome for 1 min every 10 min over 180 min. Fifteen minutes after 5-HT drug injection, all rats received L-DOPA (6 mg·kg−1) and were rated for AIMs for 1 min every 10 min over 180 min.
*
P < 0.001 versus vehicle.